Baumann M, Krause M, Overgaard J, Debus J, Bentzen SM, Daartz J, et al. Radiation oncology in the era of precision medicine. Nat Rev Cancer. 2016;16:234–49.
Xie D, Cheng W, Lv S, Zhong R, Wang L, Hu J, et al. Target delineation and dose prescription of adaptive replanning intensity-modulated radiotherapy for nasopharyngeal carcinoma. Cancer Commun (Lond). 2019;39:18.
Teh BS, Lewis GD, Mai W, Pino R, Ishiyama H, Butler EB. Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer. Cancer Commun (Lond). 2018;38:11.
Barth RF, Mi P, Yang W. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond). 2018;38:35.
Barth RF, Zhang Z, Liu T. A realistic appraisal of boron neutron capture therapy as a cancer treatment modality. Cancer Commun (Lond). 2018;38:36.
Particle Therapy Co-Operative Group. Statistics of patients treated in particle therapy facilities worldwide. https://www.ptcog.ch/index.php/patient-statistics (2019). Accessed Sept 23, 2019.
Newhauser WD, Zhang R. The physics of proton therapy. Phys Med Biol. 2015;60:R155–209.
Stuschke M, Kaiser A, Abu-Jawad J, Pöttgen C, Levegrün S, Farr J. Re-irradiation of recurrent head and neck carcinomas: comparison of robust intensity modulated proton therapy treatment plans with helical tomotherapy. Radiat Oncol. 2013;8:93.
Kandula S, Zhu X, Garden AS, Gillin M, Rosenthal DI, Ang KK, et al. Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies: a treatment planning comparison. Med Dosim. 2013;38:390–4.
Kooy HM, Grassberger C. Intensity modulated proton therapy. Br J Radiol. 2015;88:20150195.
Mohan R, Grosshans D. Proton therapy—present and future. Adv Drug Deliv Rev. 2017;109:26–44.
Jakobi A, Bandurska-Luque A, Stützer K, et al. Identification of patient benefit from proton therapy for advanced head and neck cancer patients based on individual and subgroup normal tissue complication probability analysis. Int J Radiat Oncol Biol Phys. 2015;92:1165–74.
van der Laan HP, van de Water TA, van Herpt HE, et al. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: a planning comparative study. Acta Oncol. 2013;52:561–9.
Wang LW, Liu YH, Chou FI, Jiang SH. Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing-Hua Open Pool Reactor. Cancer Commun (Lond). 2018;38:37.
Holliday EB, Kocak-Uzel E, Feng L, Thaker NG, Blanchard P, Rosenthal DI, et al. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: a case-matched control analysis. Med Dosim. 2016;41:189–94.
Apinorasethkul O, Kirk M, Teo K, Swisher-McClure S, Lukens JN, Lin A. Pencil beam scanning proton therapy vs rotational arc radiation therapy: a treatment planning comparison for postoperative oropharyngeal cancer. Med Dosim. 2017;42:7–11.
Eekers DB, Roelofs E, Jelen U, Kirk M, Granzier M, Ammazzalorso F, et al. Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial. Radiother Oncol. 2016;121:387–94.
Blanchard P, Gunn GB, Lin A, Foote RL, Lee NY, Frank SJ. Proton therapy for head and neck cancers. Semin Radiat Oncol. 2018;28:53–63.
Waddle MR, Heckman M, Diehl NN, Stross W, Miller D, Kaleem T, Miller RC, May BC, Peterson JL, Vallow LA, Tzou KS. Survival after proton and photon radiation therapy in patients with head and neck cancers: a study of the national cancer database. Int J Radiat Oncol Biol Phys. 2018;100:1330.
Wei KR, Zheng RS, Zhang SW, Liang ZH, Li ZM, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer. 2017;36:90.
Xue F, Hu CS, He XY. Effects of dosimetric inadequacy on local control and toxicities in the patients with T4 nasopharyngeal carcinoma extending into the intracranial space and treated with intensity-modulated radiotherapy plus chemotherapy. Chin J Cancer. 2017;36:76.
Widesott L, Pierelli A, Fiorino C, Dell’oca I, Broggi S, Cattaneo GM, et al. Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. Int J Radiat Oncol Biol Phys. 2008;72:589–96.
Lewis GD, Holliday EB, Kocak-Uzel E, Hernandez M, Garden AS, Rosenthal DI, Frank SJ. Intensity-modulated proton therapy for nasopharyngeal carcinoma: decreased radiation dose to normal structures and encouraging clinical outcomes. Head Neck. 2016;38(Suppl 1):E1886–95.
Holliday EB, Frank SJ. Proton therapy for nasopharyngeal carcinoma. Chin Clin Oncol. 2016;5:25.
Peng H, Chen L, Guo R, Zhang Y, Li WF, Mao YP, et al. Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes. Chin J Cancer. 2017;36:32.
Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98.
De Gonzalez AB, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12:353–60.
Dasu A, Flejmer AM, Edvardsson A, Witt NP. Normal tissue sparing potential of scanned proton beams with and without respiratory gating for the treatment of internal mammary nodes in breast cancer radiotherapy. Phys Med. 2018;52:81–5.
Taylor CW, Kirby AM. Cardiac side-effects from breast cancer radiotherapy. Clin Oncol (R Coll Radiol). 2015;27:621–9.
Fagundes MA, Pankuch M, Hartsell W, Ward C, Fang LC, Cahlon O, McNeeley S, et al. Cardiac-sparing postmastectomy proton radiation therapy for women with stage III, loco-regional, breast cancer: a dosimetric comparison study. Int J Radiat Oncol Biol Phys. 2013;87:S245.
MacDonald SM, Jimenez R, Paetzold P, Adams J, Beatty J, DeLaney TF, et al. Proton radiotherapy for chest wall and regional lymphatic radiation; dose comparisons and treatment delivery. Radiat Oncol. 2013;8:71.
Patel SA, Lu HM, Nyamwanda JA, Jimenez RB, Taghian AG, MacDonald SM, et al. Postmastectomy radiation therapy technique and cardiopulmonary sparing: a dosimetric comparative analysis between photons and protons with free breathing versus deep inspiration breath hold. Pract Radiat Oncol. 2017;7:e377–84.
Cuaron JJ, Chon B, Tsai H, Goenka A, DeBlois D, Ho A, et al. Early toxicity in patients treated with postoperative proton therapy for locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2015;92:284–91.
Partridge M, Ramos M, Sardaro A, Brada M. Dose escalation for non-small cell lung cancer: analysis and modelling of published literature. Radiother Oncol. 2011;99:6–11.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–99.
Gomez DR, Chang JY. Accelerated dose escalation with proton beam therapy for non-small cell lung cancer. J Thorac Dis. 2014;6:348–55.
Berman AT, Teo BK, Dolney D, Swisher-McClure S, Shahnazi K, Both S, et al. An in silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer. Radiat Oncol. 2013;8:144.
Chang JY, Li H, Zhu XR, Liao Z, Zhao L, Liu A, et al. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014;90:809–18.
Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II–III inoperable non-small cell lung cancer. Radiother Oncol. 2015;115:367–72.
Kim H, Pyo H, Noh JM, Lee W, Park B, Park HY, et al. Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy. Radiat Oncol. 2019;14:19.
Nantavithya C, Gomez DR, Wei X, Komaki R, Liao Z, Lin SH, et al. Phase 2 study of stereotactic body radiation therapy and stereotactic body proton therapy for high-risk, medically inoperable, early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2018;101:558–63.
Nakajima K, Iwata H, Ogino H, Hattori Y, Hashimoto S, Toshito T, et al. Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer. Radiat Oncol. 2018;13:199.
Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, et al. Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer: final results of a phase 2 study. JAMA Oncol. 2017;3:e172032.
Liao Z, Lee JJ, Komaki R, Gomez DR, O’Reilly MS, Fossella FV, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:1813–22.
Cozzi L, Comito T, Fogliata A, Franzese C, Tomatis S, Scorsetti M. Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma. PLoS ONE. 2018;13:e0201992.
Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol. 2014;20:3100–11.
Toramatsu C, Katoh N, Shimizu S, Nihongi H, Matsuura T, Takao S, et al. What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy. Radiat Oncol. 2013;8:48.
Yoo GS, Yu JI, Park HC. Proton therapy for hepatocellular carcinoma: current knowledges and future perspectives. World J Gastroenterol. 2018;24:3090–100.
Sugahara S, Oshiro Y, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2010;76:460–6.
Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-Institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2016;34:460–8.
Bush DA, Smith JC, Slater JD, Volk ML, Reeves ME, Cheng J, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. Int J Radiat Oncol Biol Phys. 2016;95:477–82.
Deville C, Jain A, Hwang WT, Woodhouse KD, Both S, Wang S, et al. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy. Acta Oncol. 2018;57:1506–14.
Goddard LC, Brodin NP, Bodner WR, Garg MK, Tomé WA. Comparing photon and proton-based hypofractioned SBRT for prostate cancer accounting for robustness and realistic treatment deliverability. Br J Radiol. 2018;91:20180010.
Fellin F, Azzeroni R, Maggio A, Lorentini S, Cozzarini C, Di Muzio N, et al. Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: a treament planning comparison. Radiother Oncol. 2013;107(2):207–12.
Takagi M, Demizu Y, Terashima K, Fujii O, Jin D, Niwa Y, et al. Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med. 2017;6:2234–43.
Colaco RJ, Hoppe BS, Flampouri S, McKibben BT, Henderson RH, Bryant C, et al. Rectal toxicity after proton therapy for prostate cancer: an analysis of outcomes of prospective studies conducted at the University of Florida Proton Therapy Institute. Int J Radiat Oncol Biol Phys. 2015;91:172–81.
Leroy R, Benahmed N, Hulstaert F, Van Damme N, De Ruysscher D. Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. Int J Radiat Oncol Biol Phys. 2016;95:267–78.
Huynh M, Marcu LG, Giles E, Short M, Matthews D, Bezak E. Current status of proton therapy outcome for paediatric cancers of the central nervous system—analysis of the published literature. Cancer Treat Rev. 2018;70:272–88.
Phan J, Sio TT, Nguyen TP, Takiar V, Gunn GB, Garden AS, et al. Reirradiation of head and neck cancers with proton therapy: outcomes and analyses. Int J Radiat Oncol Biol Phys. 2016;96:30–41.
Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Liao Z, et al. Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Oncol. 2018;8:58–65.
Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104:1129–37.
Particle Therapy Co-operative Group. Particle therapy facilities in clinical operation. https://www.ptcog.ch/index.php/facilities-in-operation. (2019). Accessed Sept 23, 2019.
Lundkvist J, Ekman M, Ericsson SR, Jönsson B, Glimelius B. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol. 2005;44:850–61.
Mailhot VR, Kim J, Hollander A, Hattangadi-Gluth J, Michalski J, Tarbell NJ, et al. Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children. Cancer. 2015;121:1694–702.
Mailhot VRB, Kim J, Bussière M, Hattangadi J, Hollander A, Michalski J, et al. Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. Cancer. 2013;119:4299–307.
Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer. 2016;122:1483–501.
Holliday E, Garden AS, Fuller CD, et al. Gastrostomy tube rates decrease by over 50% in patients with nasopharyngeal cancer treated with intensity-modulated proton therapy (IMPT): a case–control study. Int J Radiat Oncol Biol Phys. 2014;90:S528.
Lievens Y, Verhaeghe N, DeNeve W, et al. Proton radiotherapy for locally-advanced non-small cell lung cancer, a cost-effective alternative to photon radiotherapy in Belgium. 2013;S8:S839–40.
Lundkvist J, Ekman M, Ericsson SR, Isacsson U, Jönsson B, Glimelius B. Economic evaluation of proton radiation therapy in the treatment of breast cancer. Radiother Oncol. 2005;75:179–85.